BRAF Mutation (V600E) Prevalence in Mexican Patients Diagnosed with Melanoma

Zepeda-Lopez, Priscilla Denise; Salas‐Alanís, Julio C.; Toussaint–Caire, Sonia; Gutiérrez-Mendoza, Daniela; Vega‐Memije, Elisa; Silva, Saúl Lino; Fajardo-Ramírez, Óscar R; Alcazar, Gregorio; Moreno-Treviño, María Guadalupe; Barrera-Saldaña, Hugo A.

doi:10.1159/000445939

Cited by 6 publications

(7 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In Mexican patients, two previous studies searching for BRAF V600E mutations found a distant frequency, from 6.4% 24 to 73%, 25 explained by the heterogeneity of the populations analyzed (from the center and northeast of the country, respectively) and the size of the sample analyzed (< 50 patients). The current study shows the correlation of the mutation with clinical characteristics is similar to those in other populations, 15 although it was not feasible to perform a deeper analysis because of incomplete clinical information.…”

Section: Discussionmentioning

confidence: 78%

“…In our study, the central part of the country was the region with the highest prevalence of BRAF mutation (41.8%), as observed in a previous study. 24 This might be related to the sample supply and the general ethnic mix in the country. In Mexico, larger epidemiologic and educational efforts are needed to determine the current incidence of melanoma, as are better data collection tools and definition of the characteristics of the different regions of the country to perform better studies of clinicopathologic correlation.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Frequency of BRAF V600E Mutation in the Mexican Population of Patients With Metastatic Melanoma

Ruiz-García¹,

Matus-Santos²,

Guadarrama-Orozco³

et al. 2018

JGO

View full text Add to dashboard Cite

PurposeThe BRAF V600E mutation has been described in melanomas occurring in the Caucasian, European, and Asian populations. However, in the Mexican population, the status and clinical significance of BRAF mutation has not been researched on a large scale.MethodsConsecutive BRAF-tested Mexican patients with metastatic melanoma (n = 127) were analyzed for mutations in exon 15 of the BRAF gene in genomic DNA by real-time polymerase chain reaction technology for amplification and detection. The results were correlated with the clinical-pathologic features and the prognosis of the patients.ResultsThe frequency of somatic mutation V600E within the BRAF gene was 54.6% (43 of 127 patients). Nodular melanoma was the most prevalent subtype in our population, with BRAF mutations in 37.2% (16 of 55 patients). In contrast, superficial spread had a frequency of 18.6% BRAF mutation (eight of 24). Other clinicopathologic features were assessed to correlate with the mutation status.ConclusionThis study searched for the most prevalent BRAF V600E mutation type in melanoma in a heterogeneous population from Mexico. Nodular melanoma was found to be the most prevalent in metastatic presentation and the presence of BRAF V600E mutation, perhaps related to the mixed ancestry; in the north, ancestry is predominantly European and in the south, it is predominantly Asian. The outcomes of the mutation correlations were similar to those found in other populations.

show abstract

Section: Discussionmentioning

confidence: 78%

Section: Discussionmentioning

confidence: 99%

Frequency of BRAF V600E Mutation in the Mexican Population of Patients With Metastatic Melanoma

Ruiz-García¹,

Matus-Santos²,

Guadarrama-Orozco³

et al. 2018

JGO

View full text Add to dashboard Cite

show abstract

“…This could be explained by genetic differences between Caucasian and mestizo Mexican populations; in a recent study including patients from USA and Australia, those tumours with NRAS+ and BRAF+ mutations were significantly associated with trunk localisation . In a Caucasian population, the BRAF+ mutation was found in 30%, while in a study from Central Mexico this mutation was found in only 6.4% and without association to the localisation of the tumour …”

Section: Discussionmentioning

confidence: 96%

Cutaneous melanoma in patients from western Mexico: Clinical pathology characteristics and their relationship to prognosis

et al. 2019

View full text Add to dashboard Cite

Background/Objective: Melanoma is the third most frequent malignant neoplasm in skin. The majority of information available comes from studies performed in Caucasian populations. Our objective was to investigate the clinico-pathological characteristics in Mexican patients with cutaneous melanoma and the relationship these characteristics had to prognosis.Methods: A retrospective study included patients with a histopathological diagnosis of melanoma who were attended at a tertiary level Dermatology Institute over a 10-year period. Age, gender, anatomical location; histopathological subtype, Breslow thickness, Clark level; presence of ulceration, metastasis, anatomical-pathological stage and survival were investigated. To assess the data, descriptive statistics, chi-squared or the Fisher exact test and Kaplan-Meier curves were used.Results: There were 323 patients included. The overall survival rate was 77% with an average follow-up of 7 years. The lowest survival was statistically related to the following: higher age (>65 years), localisation in palms/soles, histopathological nodular subtype, presence of ulceration, Breslow thickness >4.0 mm, Clark level V, the presence of metastasis and stage IV disease. Conclusions:Our results relay the characteristics and prognosis of patients with the diagnosis of cutaneous melanoma in western Mexico.

show abstract

“…The BRAF oncogene transmits growth signals to protein kinases on the RAS oncogenic pathway. The most important and frequent mutation of BRAF is V600E, which results in the substitution of the valine amino acid by glutamic acid at position 600, thereby dysregulating the activation map of the kinase/ERK signaling pathway, leading finally to melanoma genesis (14,15). Therefore, it can be a good subject for studies to differentiate benign and malignant skin neoplasms, thus predicting tumor behavior and planning specific target therapy by new drugs such as vemurafenib against BRAF V600E (12).…”

Section: Introductionmentioning

confidence: 99%

“…There are some molecular and immunostaining-based studies, both in in vitro and in vivo settings, with in- consistent results regarding the prevalence, clinical implications and correlation with pathologic and prognostic variables of BRAF V600E in skin neoplasms 20 (13). The frequency of the BRAF V600E mutation was reported as ranging from 6.4% (15) to as high as 70.1% (16) in the skin melanomas of patients around the world. We were encouraged for the first time to investigate the expression of mutant BRAF V600E in a sample of Iranian patients in the north of Iran that had suffered from pigmented skin neoplasms.…”

Section: Introductionmentioning

confidence: 99%

Immunohistochemical Investigation of Mutant BRAF V600E in Common Pigmented Skin Neoplasms, Study on a Sample of Iranian Patients

Ghasemi

Emadian

et al. 2018

Iran J Pathol

View full text Add to dashboard Cite

Background & Objective: This study was designed for the first time for the detec- tion of mutant BRAF V600E and its correlation with clinicophathologic features in a sample of Iranian patients with pathologically proved pigmented skin neoplasms. Methods: 82 paraffin-embedded blocks, including melanocytic nevi, malignant melanoma, Basel cell carcinoma, and squamous cell carcinoma were evaluated for BRAF V600E expression by immunohistochemistry in the patients admitted to Ibn Sina Hospital, in the city of Sari, Mazandaran province, North of Iran. The evaluation of immunohistochemical staining was performed by two of the authoring pathologists, and staining intensity was graded from negative (0), weak (1+), moderate (2+) to strong (3+). If twenty percent (or greater) of the tumor cells showed modest to strong cytoplasmic immunoreactivity (score 3+), the neoplasm was considered positive for this tumor marker. Results: Among 82 studied patients, 12 cases (60%) of the malignant melanoma group revealed a high intensity of immunostaining for BRAF V600E, while a signifi- cant expression of this marker did not occur in the other investigated skin neoplasm. A great relation between BRAF (V600E) expression and the histologic type of skin cancer was noted. No significant relationship with other parameters such as gender, age, and the grade differentiation of the non-melanoma skin cancer was found. BRAF V600E was weakly correlated with the Clark level of cutaneous malignant melanoma. Conclusion: This data provided further evidence for the strong role of the BRAF V600E mutation in the development of cutaneous malignant melanoma, compared to non-melanoma skin cancers in the North of Iran. We advised future studies to evaluate the beneficial effects of anti-BRAF V600E target therapy on the Iranian melanoma patient who harbors this marker by way of immunostaining tumor tissue.

show abstract

BRAF Mutation (V600E) Prevalence in Mexican Patients Diagnosed with Melanoma

Cited by 6 publications

References 14 publications

Frequency of BRAF V600E Mutation in the Mexican Population of Patients With Metastatic Melanoma

Frequency of BRAF V600E Mutation in the Mexican Population of Patients With Metastatic Melanoma

Cutaneous melanoma in patients from western Mexico: Clinical pathology characteristics and their relationship to prognosis

Immunohistochemical Investigation of Mutant BRAF V600E in Common Pigmented Skin Neoplasms, Study on a Sample of Iranian Patients

Contact Info

Product

Resources

About